Cyclo Therapeutics (CYTH.US) was first covered by Ascendiant Capital, giving it a buy rating, with a target price of $2.60.
Zhitong FinanceApr 22 17:41
Cyclo Therapeutics Analyst Ratings
BenzingaApr 22 17:35
Ascendiant Capital Initiates Coverage On Cyclo Therapeutics With Buy Rating, Announces Price Target of $2.6
BenzingaApr 22 17:40
Analysts Offer Insights on Healthcare Companies: Cyclo Therapeutics (CYTH), CytomX Therapeutics (CTMX) and Pacific Biosciences (PACB)
TipRanksApr 22 16:20
Buy Rating Affirmed for Cyclo Therapeutics on Strong Clinical and Financial Prospects
TipRanksMar 20 03:35
Cyclo Therapeutics Analyst Ratings
BenzingaSep 27, 2023 21:33
No Data
No Data